
Dermatology
Latest News

Safety Considerations Highlighted for Alopecia Treatments During Breastfeeding

Review Highlights Benefits, Drawbacks of Dual Biologic Therapy in Dermatology
Latest Videos

CME Content
More News

In this video, the fifth in a 6-part series, panelists discuss recent advancements in PsO management.

In this video, the fourth in a 6-part series, panelists discuss recent advancements in PsO management.

In this video, the third in a 6-part series, panelists discuss recent advancements in PsO management.

In this video, the second in a 6-part series, panelists discuss recent advancements in PsO management.

In this video, the first in a 6-part series, panelists discuss recent advancements in PsO management.

This announcement highlights Pelthos Therapeutics’ launch of berdazimer (ZELSUVMI) topical gel 10.3% for molluscum contagiosum.

These ADHAND trial data highlight the results of tralokinumab in those with atopic dermatitis on the hands who are candidates for systemic therapy.

Findings highlight the ongoing burden of generalized pustular psoriasis and suggest patients may benefit from targeted biologic therapies like the FDA-approved spesolimab.

In ARRECTOR, patients reported symptom relief and improved quality of life as early as week 2, with strong tolerability and safety through week 8.

This clinical episode of Skin of Color Savvy features a discussion on UV safety and photo protection in patients with skin of color.

Based on reduced FOXP3+ expression in patients, investigators have drawn a strong correlation between MetS due to psoriasis and immune dysregulation.

New research reveals significant links between alopecia areata and mental health issues, emphasizing the need for comprehensive care in affected individuals.


Phase 3 trials have shown low rates of serious adverse events with ruxolitinib cream in pediatric and adult patients with atopic dermatitis and non-segmental vitiligo.

Findings suggest pediatric patients with guttate or inverse psoriasis may warrant evaluation for pharyngeal or anogenital bacterial infections.

Gastrointestinal disorders, atopic conditions, and other diseases may have similar or shared pathogenetic mechanisms with AA, based on recent research.

Overall, older treatment strategies such as methotrexate and phototherapy still led the way for cost-effectiveness.

In this session at SDPA, Griffith and Sebat review clinically relevant articles from the prior 12 months from the top dermatology journals.

Check out insights from SDPA 2025 on eczema, alopecia, vitiligo, burnout, and JAK inhibitor workups—key tips to improve dermatology care.

These 16-week findings have been announced by Apogee Therapeutics on APG777 in patients with moderate-to-severe atopic dermatitis.

These data point to several hidradenitis suppurativa drugs as most impactful for those with moderate-to-severe disease, based on Hidradenitis Suppurativa Clinical Response.

Following the AAD guideline update on atopic dermatitis treatments, Sidbury speaks to the significance of the guideline recommendations for patients and clinicians.

Sidbury highlights updates to previous guidelines on the management of atopic dermatitis using approved topical and systemic therapies.

This FDA news recap highlights some of the most notable approvals and actions by the organization in dermatology during Q2 2025.

Discover groundbreaking FDA approvals in 2025 that redefine treatment standards, enhance patient care, and address critical public health needs.


















































